Get 40% Off
🚀 Our AI Picked 6 Stocks that Jumped +25% in Q1. Which Picks Will Soar in Q2?Unlock full list

BioNTech shares gain as BMO sets $127 target with Outperform rating

EditorAhmed Abdulazez Abdulkadir
Published 02/23/2024, 05:19 AM
Updated 02/23/2024, 05:19 AM
© Reuters.

On Friday, BMO Capital Markets initiated coverage on shares of BioNTech SE (NASDAQ:BNTX), a company recognized for its pioneering work in mRNA technology, particularly in cancer and infectious disease therapies. The firm set a price target of $127 and issued an Outperform rating for the stock.

BioNTech, which saw significant growth during the COVID-19 pandemic, has experienced a pullback in its stock value, attributed to the uncertainties surrounding the pandemic's future. BMO Capital Markets sees this as an opportunity, pointing out that the market's focus on COVID-19 has overshadowed BioNTech's promising oncology pipeline. This pipeline is anticipated to potentially provide substantial upside to the company's shares as its mid and late-stage programs advance towards clinical de-risking in the years 2024 and 2025.

The firm's coverage comes at a time when BioNTech has a substantial cash reserve, approximately €17 billion, which it plans to use for business development and further diversification of its pipeline. This financial strength could enable BioNTech to enhance its portfolio and potentially increase shareholder value.

BMO's coverage note also highlights the potential of BioNTech's technology platform beyond its success with the COVID-19 vaccine. The company's focus on harnessing the immune system to combat cancer and other infectious diseases positions it at the forefront of medical innovation.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.